INOTREM
Inotrem S.A., a biotechnology company specialized in the development of immunotherapies targeting the TREM-1 pathway, announced today that it has obtained authorization to launch its phase IIa clinical trial in COVID-19 patients in France, Belgium and the USA.
For this study, Inotrem received a non-dilutive funding as part of the call for proposals PSPC Covid, financed by the Investments d’Avenir Program which managed on behalf of the French government by Bpifrance, France’s public investment bank. Inotrem with its partners the CHRU of Nancy and the CHU of Limoges, was one of the 6 French biotech companies who benefited from this programme to support the research and development of therapeutic solutions targeting COVID-19.
The goal of this first exploratory study is to determine the safety and tolerability and potential signals of efficacy of nangibotide in critically ill patients with COVID-19 with features of systemic inflammation. The objective of this project is to have a positive impact on the severity of the respiratory failure, reduce duration of mechanical ventilation, length of stay in ICU and reduce mortality. Sixty patients will be enrolled in Europe and in the United States. This study follows an observational study in 27 patients, conducted by Prof. Sébastien Gibot at the CHRU of Nancy, which showed an increased expression of the TREM-1 pathway in severe COVID-19 patients. TREM-1 is an immunomodulatory receptor expressed on innate immune cells which amplifies and maintains inflammation.
Previous clinical studies with nangibotide demonstrated its safety and tolerability in patients suffering from septic shock, which is also characterized by a systemic inflammatory reaction. Pre-clinical models have shown that nangibotide inhibits the amplification of the immune response caused by the activation of TREM-1 and was able to restore appropriate inflammatory response, vascular function, and improved survival in septic shock models. Inotrem is currently conducting a Phase IIb trial (ASTONISH) to treat septic shock patients with nangibotide in 6 European countries and in the United States. It is also developing, with Roche Diagnostics, a companion diagnostic test to identify septic schock patients more likely to benefit from its nangibotide treatment.
Coronavirus disease 2019 is a new pandemic disease that arises as a consequence of infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). The optimum treatment strategy in the management of critically ill patients with COVID-19 continues to evolve and, in addition to supportive therapies such as mechanical ventilation, vasopressors and renal replacement therapy, may include immunomodulatory approaches, such as nangibotide, in patients with severe disease.
Professor Sébastien Gibot, Nancy University Hospital and coordinating investigator said “We observed that the TREM-1 pathway was activated in severe forms of COVID-19. Nangibotide is a TREM-1 inhibitor and has the potential to restore an appropriate immune response. We are hoping to demonstrate that nangibotide will reduce the duration of hospitalization and mortality of critically ill patients suffering from COVID-19”.
Jean-Jacques Garaud, CEO of Inotrem, declared: “We are very pleased with both the granting of this financial support and the clearance to start our clinical trial. The French administration has been very effective in working in a coordinated and rapid fashion.”
About Inotrem
Inotrem S.A. is a biotechnology company specialized in immunotherapy for acute and chronic inflammatory syndromes. The company has developed a new concept of immunomodulation that targets the TREM-1 pathway to control unbalanced inflammatory responses. Through its proprietary technology platform, Inotrem has developed the first-in-class TREM-1 inhibitor, LR12 (nangibotide), with potential applications in a number of therapeutic indications such as septic shock and myocardial infarction. In parallel, Inotrem has also launched another program to develop a new therapeutic modality targeting chronic inflammatory diseases. The company was founded in 2013 by Dr. Jean-Jacques Garaud, a former head of research and early development at the Roche Group, Prof. Sébastien Gibot and Dr. Marc Derive. Inotrem is supported by leading European and North American investors.
www.inotrem.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200722005598/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Altman Solon Selects Mindbreeze to Power Knowledge Management and Collaboration Across the Organization10.11.2025 16:01:00 CET | Press release
Mindbreeze, a leading global provider of AI-based knowledge management solutions, today announced that Altman Solon, the world’s largest strategy consulting firm focused exclusively on telecommunications, media, and technology (TMT), has purchased Mindbreeze InSpire. The collaboration began in July 2025 with a trial of the Mindbreeze Insight Workplace, designed to unify Altman Solon’s SharePoint and web-based data sources into a single point of entry for organizational knowledge. Before partnering with Mindbreeze, Altman Solon sought to enhance how its global teams accessed and shared knowledge across systems, a challenge common among consulting firms with vast, fast-growing data ecosystems. The company had built a strong foundation in SharePoint for managing structured project data, but its native search capabilities limited visibility across platforms. Project information was distributed across several secure repositories, making it difficult to form a single, holistic view of our co
NIQ to Present at 2025 J.P. Morgan Ultimate Services Investor Conference10.11.2025 16:00:00 CET | Press release
NielsenIQ (NYSE: NIQ) (the “Company”, or "NIQ"), a leading global consumer intelligence company, today announced that Jim Peck, Chairman and CEO, will participate in a fireside chat at the J.P. Morgan Ultimate Services Investor Conference on Tuesday, November 18, 2025 at 10:20 am ET. A live webcast of the presentation will be available on the NIQ investor relations website at https://investors.nielseniq.com. A replay will also be available on the Company's website following the conclusion of the presentation. About NielsenIQ NielsenIQ (NIQ) is a leading consumer intelligence company, delivering the most complete understanding of consumer buying behavior and revealing new pathways to growth. Our global reach spans over 90 countries covering approximately 85% of the world’s population and more than $7.2 trillion in global consumer spend. With a holistic retail read and the most comprehensive consumer insights—delivered with advanced analytics through state-of-the-art platforms—NIQ delive
Decagon Announces Commercial Pilot with Deutsche Telekom and Strategic Investment from T.Capital to Fuel Enterprise Growth10.11.2025 16:00:00 CET | Press release
WEB SUMMIT 2025 – Decagon, the leader in conversational AI agents for concierge customer experiences, today announced a commercial pilot with global telecommunications provider Deutsche Telekom, as well as a strategic investment from T.Capital, the corporate venture arm of Deutsche Telekom. Deutsche Telekom is the world’s largest telecommunications provider by revenue and serves hundreds of millions of mobile customers across the globe. T.Capital provides early- and late-stage strategic capital to companies that have synergies with parent Deutsche Telekom. “Decagon’s powerful AI is helping businesses deliver an exceptional customer experience,” said Jonathan Abrahamson, Chief Product & Digital Officer at Deutsche Telekom. “The company's innovative approach fits perfectly to our own vision to elevate customer experiences through technology, and we look forward to both our commercial pilot and joining the roster of top-flight investors fueling the company’s impressive product velocity an
Dawex and Innovalia Group Join Forces to Accelerate the Deployment of Data Exchange Solutions in Spain10.11.2025 15:07:00 CET | Press release
Dawex, the leader in data exchange solutions, and Innovalia Group, a strategic group of technology companies specializing in digital transformation solutions, have signed a strategic collaboration agreement to drive the development of secure and sovereign data spaces in the Spanish market through a comprehensive range of products and services. The collaboration brings together two strong and complementary areas of expertise: Dawex’s technological leadership in Data Exchange and the Innovalia Group’s extensive knowledge of the Spanish industrial sector. Dawex and the Innovalia Group are joining forces to offer joint value propositions to large companies, SMEs and public entities, interested in deploying their own digital ecosystems and secure, trusted data spaces. Dawex brings its extensive technology, business and regulatory expertise in creating secure and trusted data ecosystems, such as Corporate Data Hubs, Data Marketplaces and Industry Data Spaces, to create data spaces and improv
Abdul Latif Jameel Finance and Ant International Collaborate to Grow and Strengthen MSMEs in the Kingdom with Advanced Digital Services10.11.2025 15:01:00 CET | Press release
Collaboration begins with global treasury and digitization services of Ant International's WorldFirstMoU focuses on accelerating digitalization of financial and consumer services for Saudi Arabia’s merchants and consumersAnt International is headquartered in Singapore and works with global banks, e-payment partners and industry platforms to drive inclusive growth for businesses of all sizes through its innovative fintech solutions Abdul Latif Jameel Finance, a leader in innovative financing solutions and services that is regulated by the Saudi Central Bank (SAMA), and Ant International, a leading global digital payment, digitization and financial technology provider, have signed a Memorandum of Understanding (MoU) to jointly explore opportunities in the financial technology sector in the Kingdom of Saudi Arabia. Through this collaboration, Abdul Latif Jameel Finance and Ant International will help grow and strengthen Micro, Small & Medium Enterprises (MSMEs) in Saudi Arabia with advanc
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom